152_CD GlaxoSmithKline_NNP Shareholder_NN return_NN Merger_NNP of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP Dividends_NNPS The_DT merger_NN was_VBD implemented_VBN by_IN way_NN of_IN a_DT scheme_NN of_IN arrangement_NN GlaxoSmithKline_NNP pays_VBZ dividends_NNS quarterly_RB ._.
At_IN present_JJ ,_, it_PRP is_VBZ expected_VBN and_CC became_VBD effective_JJ on_IN 27th_JJ December_NNP 2000_CD ._.
A_DT new_JJ holding_NN that_IN there_EX will_MD be_VB a_DT level_NN dividend_NN for_IN each_DT of_IN the_DT first_JJ three_CD quarters_NNS ,_, company_NN ,_, GlaxoSmithKline_NNP plc_NN ,_, acquired_VBD Glaxo_NNP Wellcome_NNP and_CC with_IN a_DT higher_JJR dividend_NN in_IN the_DT fourth_JJ quarter_NN ._.
Each_DT quarters_NNS dividend_NN SmithKline_NNP Beecham_NNP ._.
In_IN accordance_NN with_IN the_DT agreed_VBN merger_NN is_VBZ announced_VBN at_IN the_DT time_NN of_IN the_DT quarterly_JJ Results_NNS Announcement_NN ._.
terms_NNS ,_, shareholders_NNS of_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP The_NNP Board_NNP declared_VBD dividends_NNS for_IN 2002_CD as_IN follows_VBZ :_: received_VBN ,_, in_IN exchange_NN for_IN their_PRP$ existing_VBG shares_NNS ,_, shares_NNS in_IN 2002_CD 2001_CD GlaxoSmithKline_NNP as_IN follows_VBZ :_: Dividends_NNS per_IN share_NN pence_NN pence_NN First_NNP interim_JJ -_: paid_VBN 4th_JJ July_NNP 2002_CD 9_CD 9_CD for_IN each_DT Glaxo_NNP Wellcome_NNP ordinary_JJ share_NN 1_CD GlaxoSmithKline_NNP Second_NNP interim_NN -_: paid_VBN 3rd_CD October_NNP 2002_CD 9_CD 9_CD ordinary_JJ share_NN Third_JJ interim_NN -_: paid_VBN 3rd_CD January_NNP 2003_CD 9_CD 9_CD for_IN each_DT SmithKline_NNP Beecham_NNP ordinary_JJ share_NN 0.4552_CD Fourth_JJ interim_NN -_: payable_JJ 17th_JJ April_NNP 2003_CD 13_CD 12_CD GlaxoSmithKline_NNP ordinary_JJ shares_NNS ._.
Total_JJ 40_CD 39_CD In_IN the_DT case_NN of_IN shares_NNS held_VBN as_IN American_JJ Depositary_NNP Shares_NNP ADSs_NNP ,_, holders_NNS of_IN Glaxo_NNP Wellcome_NNP ADRs_NNPS and_CC holders_NNS of_IN SmithKline_NNP Dividends_NNPS ADSs_NNP Beecham_NNP ADRs_NNPS received_VBD :_: As_IN a_DT guide_NN to_TO holders_NNS of_IN ADRs_NNS ,_, the_DT tables_NNS below_IN set_VBN out_RP the_DT dividends_NNS for_IN each_DT Glaxo_NNP Wellcome_NNP ADS_NNPS -_: 1_CD GlaxoSmithKline_NNP ADS_NNPS paid_VBD per_IN ADS_NNPS in_IN US_NNP dollars_NNS in_IN the_DT last_JJ five_CD years_NNS ._.
The_DT dividends_NNS are_VBP for_IN each_DT SmithKline_NNP Beecham_NNP ADS_NNPS -_: 1.138_CD GlaxoSmithKline_NNP ADSs_NNP adjusted_VBN for_IN UK_NNP tax_NN credit_NN less_RBR withholding_VBG tax_NN ,_, where_WRB applicable_JJ ,_, and_CC are_VBP translated_VBN into_IN US_NNP dollars_NNS at_IN applicable_JJ exchange_NN rates_NNS ._.
GlaxoSmithKline_NNP shares_NNS commenced_VBD trading_NN on_IN the_DT London_NNP Stock_NNP Exchange_NNP and_CC GlaxoSmithKline_NNP ADSs_NNP commenced_VBD trading_NN on_IN the_DT Since_IN 6th_JJ April_NNP 1999_CD ,_, claims_VBZ for_IN refunds_NNS of_IN tax_NN credits_NNS on_IN dividends_NNS New_NNP York_NNP Stock_NNP Exchange_NNP on_IN 27th_JJ December_NNP 2000_CD ._.
from_IN the_DT UK_NNP tax_NN authorities_NNS are_VBP of_IN negligible_JJ benefit_NN to_TO US_NNP shareholders_NNS ._.
Taxation_NNP Year_NNP GSK_NNP $_$ GW_CD $_$ SB_CD $_$ General_JJ information_NN concerning_VBG the_DT UK_NNP and_CC US_NNP tax_NN effects_NNS of_IN 2002_CD 1.24_CD share_NN ownership_NN is_VBZ set_VBN out_RP in_IN `_`` Taxation_NNP information_NN for_IN shareholders_NNS '_POS ._.
2001_CD 1.11_CD 2000_CD 1.10_CD 0.87_CD Share_NN price_NN 1999_CD 1.14_CD 0.86_CD 2002 2001 2000 1998_CD 1.19_CD 0.81_CD GSK_NNP GW_NNP SB_NNP Dividends_NNPS paid_VBD to_TO Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP ADR_NNP At_IN 1st_CD January_NNP 17.23_CD 18.90_CD 17.50_CD 7.90_CD holders_NNS are_VBP expressed_VBN as_IN dividends_NNS per_IN GlaxoSmithKline_NNP ADS_NNPS ._.
High_NNP during_IN the_DT year_NN 17.80_CD 20.32_CD 21.10_CD 9.55_CD Low_NNP during_IN the_DT year_NN 10.57_CD 16.26_CD 14.40_CD 6.71_CD Dividend_NN calendar_NN At_IN 26th_JJ December_NNP 18.42_CD 8.33_CD At_IN 31st_CD December_NNP 11.92_CD 17.23_CD 18.90_CD Fourth_JJ quarter_NN 2002_CD Decrease_NN increase_NN 31_CD %_NN 9_CD %_NN 5_CD %_NN 5_CD %_NN Ex-dividend_NN date_NN 19th_JJ February_NNP 2003_CD Record_NNP date_NN 21st_CD February_NNP 2003_CD The_DT table_NN above_IN sets_NNS out_IN the_DT middle_JJ market_NN closing_NN prices_NNS derived_VBN Payable_JJ 17th_JJ April_NNP 2003_CD from_IN the_DT London_NNP Stock_NNP Exchange_NNP Daily_NNP Official_NNP List_NN ._.
First_JJ quarter_NN 2003_CD The_DT companys_NNS share_VBP price_NN declined_VBD by_IN 31_CD per_IN cent_NN in_IN 2002_CD from_IN Ex-dividend_NN date_NN 7th_JJ May_NNP 2003_CD a_DT price_NN of_IN 17.23_CD at_IN 1st_CD January_NNP 2002_CD to_TO 11.92_CD at_IN 31st_CD Record_NNP date_NN 9th_CD May_NNP 2003_CD December_NNP 2002_CD ._.
This_DT compares_VBZ with_IN a_DT decrease_NN in_IN the_DT FTSE_NNP 100_CD Payable_JJ 3rd_CD July_NNP 2003_CD index_NN of_IN 24_CD per_IN cent_NN during_IN the_DT year_NN ._.
In_IN the_DT two_CD years_NNS since_IN the_DT merger_NN ,_, the_DT share_NN price_NN has_VBZ declined_VBN by_IN 37_CD per_IN cent_NN from_IN 18.90_CD Second_JJ quarter_NN 2003_CD at_IN 1st_CD January_NNP 2001_CD which_WDT is_VBZ in_IN line_NN with_IN a_DT similar_JJ decrease_NN in_IN the_DT Ex-dividend_NN date_NN 30th_JJ July_NNP 2003_CD FTSE_NNP 100_CD index_NN over_IN the_DT same_JJ period_NN ._.
Record_NNP date_NN 1st_CD August_NNP 2003_CD Payable_JJ 2nd_JJ October_NNP 2003_CD Market_NNP capitalization_NN The_DT market_NN capitalization_NN of_IN GlaxoSmithKline_NNP at_IN 31st_CD December_NNP Third_NNP quarter_NN 2003_CD 2002_CD was_VBD 72_CD billion_CD ._.
At_IN that_DT date_NN GlaxoSmithKline_NNP was_VBD the_DT third_JJ Ex-dividend_NN date_NN 29th_JJ October_NNP 2003_CD largest_JJS company_NN by_IN market_NN capitalization_NN on_IN the_DT FTSE_NNP index_NN ._.
Record_NNP date_NN 31st_CD October_NNP 2003_CD Payable_JJ 6th_JJ January_NNP 2004_CD SmithKline_NNP Beecham_NNP plc_NN Floating_VBG Rate_NNP Unsecured_NNP Loan_NNP Stock_NNP 1990_CD 2010_CD The_DT loan_NN stock_NN is_VBZ not_RB listed_VBN on_IN any_DT exchange_NN but_CC holders_NNS may_MD require_VB SmithKline_NNP Beecham_NNP plc_NN to_TO redeem_VB their_PRP$ loan_NN stock_NN at_IN par_NN ,_, i._FW e._FW 1_CD for_IN every_DT 1_CD of_IN loan_NN stock_NN held_VBN ,_, on_IN the_DT first_JJ business_NN day_NN of_IN March_NNP ,_, June_NNP ,_, September_NNP and_CC December_NNP ._.
Holders_NNS wishing_VBG to_TO redeem_VB all_DT or_CC part_NN of_IN their_PRP$ loan_NN stock_NN should_MD complete_VB the_DT notice_NN on_IN the_DT back_NN of_IN their_PRP$ loan_NN stock_NN certificate_NN and_CC return_VB it_PRP to_TO the_DT registrar_NN ,_, to_TO arrive_VB at_IN least_JJS 30_CD days_NNS before_IN the_DT relevant_JJ redemption_NN date_NN ._.
